Cargando…

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions

Detalles Bibliográficos
Autores principales:	Lenze, Eric J., Reiersen, Angela M., Santosh, Paramala J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077594/ https://www.ncbi.nlm.nih.gov/pubmed/35524600 http://dx.doi.org/10.1002/wps.20983

Ejemplares similares

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
por: Facente, Shelley N., et al.
Publicado: (2021)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference
por: Marcec, Robert, et al.
Publicado: (2022)

Stress cardiomyopathy and other resembling conditions
por: Raut, Monish S, et al.
Publicado: (2016)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Repurposing antimalarials and other drugs for COVID-19
por: Schlagenhauf, Patricia, et al.
Publicado: (2020)

The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
por: Reiersen, Angela M, et al.
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
por: Hoertel, Nicolas, et al.
Publicado: (2021)

Save Your Life and Others' COVID-19 Vaccine
por: Nguyen, Timothy
Publicado: (2022)

Statins and other drugs: Facing COVID-19 as a vascular disease
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Fluvoxamine Plays an Integral Role in the Alteration of Sexual Behavioral Pattern more in Females than Males
por: Santra, Ranjita
Publicado: (2012)

Co-infection with other respiratory pathogens in COVID-19 patients
por: Calcagno, Andrea, et al.
Publicado: (2021)

Computational-based drug repurposing methods in COVID-19
por: Masoudi-Sobhanzadeh, Yosef
Publicado: (2020)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

The Combinational Role of Vitamin D and Other Conditions in Multiple Sclerosis Patients
por: Sioka, Chrissa
Publicado: (2022)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Thoughts about “other” patients’ rights during COVID-19 pandemic
por: Chrysikos, Dimosthenis, et al.
Publicado: (2020)

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19
por: Gupta, Neelesh, et al.
Publicado: (2020)

Comparing COVID-19-linked neurological complications with other viral infections
por: Deng, Xiao, et al.
Publicado: (2020)

The other side of the coin: ‘centralization’ against ‘optimization’ in COVID‐19 pandemic
por: Morici, Nuccia, et al.
Publicado: (2021)

Is it safe to manage COVID-19 and other diseases simultaneously in the same hospital?
por: Perciaccante, A., et al.
Publicado: (2022)

COVID-19 deaths in children: comparison with all- and other causes and trends in incidence of mortality
por: Bhopal, S.S., et al.
Publicado: (2020)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered
por: Deltenre, Pierre, et al.
Publicado: (2021)

Vaccine hesitancy and the challenge of controlling COVID-19 and other vaccine-preventable diseases
por: Martins-Filho, Paulo Ricardo
Publicado: (2023)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Repurposing Selective Serotonin Reuptake Inhibitors for COVID-19: Rationale and Concerns
por: Navin, Karthick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_udddjs2qslj4vis5hai6c47lqj